Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population.

Perfluorooctanoate and perfluorooctanesulfonate are used in many industrial products and have been widely detected in human blood. Both chemicals are associated with tumor development in animal studies, but data on carcinogenic potential in humans are sparse. We investigated the association between plasma levels of perfluorooctanoate and perfluorooctanesulfonate and cancer risk within a prospective Danish cohort of participants with no previous cancer diagnosis at enrollment. From enrollment, between December 1, 1993, and May 31, 1997, and through July 1, 2006, we identified 713 participants with prostate cancer, 332 with bladder cancer, 128 with pancreatic cancer, and 67 with liver cancer in the entire cohort and we selected a comparison subcohort of 772. Plasma concentrations of perfluorooctanoate and perfluorooctanesulfonate were measured in each participant by use of high-pressure liquid chromatography coupled to tandem mass spectrometry. We found no clear differences in incidence rate ratios for these cancers in relation to plasma concentrations of perfluorooctanoate or perfluorooctanesulfonate. A 30%-40% increase in risk estimates for prostate cancer was observed for the three upper quartiles of perfluorooctanesulfonate concentration compared with the lowest quartile (eg, for the lowest vs the fourth quartile, incidence rate ratio = 1.38, 95% confidence interval = 0.99 to 1.93). Plasma concentrations of perfluorooctanoate and perfluorooctanesulfonate in the general Danish population appear not to be associated with risk of prostate, bladder, pancreatic, or liver cancer.

[1]  Geary W Olsen,et al.  Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. , 2007, Environmental research.

[2]  S. Greenland.  Dose‐Response and Trend Analysis in Epidemiology: Alternatives to Categorical Analysis , 1995, Epidemiology.

[3]  A. Tjønneland,et al.  Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark , 2007, Scandinavian journal of public health.

[4]  Jørn Olsen,et al.  Perfluorinated Chemicals and Fetal Growth: A Study within the Danish National Birth Cohort , 2007, Environmental health perspectives.

[5]  W. Barlow,et al.  Robust variance estimation for the case-cohort design. , 1994, Biometrics.

[6]  K. Rothman.  Biases in study design , 2002 .

[7]  M. A. Mohd,et al.  Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. , 2004, Environmental science & technology.

[8]  Storm Hh.  The Danish Cancer Registry, a self-reporting national cancer registration system with elements of active data collection. , 1991 .

[9]  A. Calafat,et al.  Perfluorochemicals in pooled serum samples from United States residents in 2001 and 2002. , 2006, Environmental science & technology.

[10]  J. Giesy,et al.  Global distribution of perfluorooctane sulfonate in wildlife. , 2001, Environmental science & technology.

[11]  A. Calafat,et al.  Perfluorinated chemicals in selected residents of the American continent. , 2006, Chemosphere.

[12]  Jeffrey H Mandel,et al.  Epidemiologic Assessment of Worker Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations and Medical Surveillance Examinations , 2003, Journal of occupational and environmental medicine.

[13]  Jürgen Angerer,et al.  Pilot study on the perfluorooctanesulfonate and perfluorooctanoate exposure of the German general population. , 2006, International journal of hygiene and environmental health.

[14]  Andrea Pfahles-Hutchens,et al.  The Applicability of Biomonitoring Data for Perfluorooctanesulfonate to the Environmental Public Health Continuum , 2006, Environmental health perspectives.

[15]  L. Shaw,et al.  Community Exposure to Perfluorooctanoate: Relationships Between Serum Concentrations and Exposure Sources , 2006, Journal of occupational and environmental medicine.

[16]  John W. Froehlich,et al.  Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers , 2007, Environmental health perspectives.

[17]  B H Alexander,et al.  Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility , 2003, Occupational and environmental medicine.

[18]  Bruce H Alexander,et al.  Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. , 2007, Annals of epidemiology.

[19]  R. Hornung,et al.  Estimation of Average Concentration in the Presence of Nondetectable Values , 1990 .

[20]  M. Roberfroid,et al.  Peroxisomal Enzymes and 8-Hydroxydeoxyguanosine in Rat Liver Treated with Perfluorooctanoic Acid , 2004, Disease markers.

[21]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[22]  W E Barlow,et al.  Analysis of case-cohort designs. , 1999, Journal of clinical epidemiology.

[23]  K. Rothman.  Epidemiology: An Introduction , 2002 .

[24]  H. Storm.  The Danish Cancer Registry, a self-reporting national cancer registration system with elements of active data collection. , 1991, IARC scientific publications.

[25]  Roger G Perkins,et al.  The Toxicology of Perfluorooctanoate , 2004, Critical reviews in toxicology.

[26]  F. Gilliland,et al.  Mortality among employees of a perfluorooctanoic acid production plant. , 1993, Journal of occupational medicine. : official publication of the Industrial Medical Association.